Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review

被引:9
|
作者
Lopez-Lopez, Jose P. [1 ,2 ]
Gonzalez, Ana Maria [1 ]
Lanza, Paola [1 ]
Lopez-Jaramillo, Patricio [1 ,3 ]
机构
[1] Univ Santander UDES, MASIRA Res Inst, Bucaramanga, Santander, Colombia
[2] Pontificia Univ Javeriana, Hosp Univ San Ignacio, Dept Internal Med, Cardiol Unit, Bogota, Colombia
[3] Univ Santander UDES, MASIRA Res Inst, Fac Ciencias Salud, Bloque G,Piso 6, Bucaramanga, Santander, Colombia
关键词
polypill; cardiovascular disease; hypertension; dyslipidemia; major cardiovascular events; DOSE COMBINATION TREATMENT; HIGH-RISK; BLOOD-PRESSURE; STRATEGY; TRIAL; DRUGS;
D O I
10.2147/VHRM.S421024
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: Higher medication adherence reduces the risk of new cardiovascular events. However, there are individual and health system barriers that lead to lower adherence. The polypill has demonstrated benefits in cardiovascular morbidity and mortality mainly driven by an increase in adherence. We aim to evaluate the impact of the polypill on adherence to cardiovascular medication, its efficacy and safety in cardiovascular disease (CVD) prevention. Methods: A systematic review following PRISMA guidelines was conducted. Databases were searched from January 2003 to December 2022. We included randomized, pragmatic, or real-world clinical trials and observational studies. The primary outcome was medication adherence, secondary outcomes were efficacy in cardiovascular disease in primary and secondary prevention and safety. Results: From the 490 publications screened, 13 met the inclusion criteria and were incorporated into a comparative table Of those included, 70% were randomized controlled trials (RCTs) and 53.8% focused on secondary prevention. Most of the studies received a high and moderate quality rating. Self-report, pill counting and, the Morisky scale were the most frequent methods to evaluate adherence (84.6%). Compared with standard medication, the polypill improved overall medication adherence by 13%, with percen-tages ranging from 7.6% to 34.9%. Moreover, a potential benefit was also observed in reducing Major Adverse Cardiovascular Events (MACE), particularly in secondary prevention studies, with hazard ratios ranged between 0.43 to 0.76. Compared to standard care, the profile of side effects was similar. Conclusion: The polypill is an effective, safe, and practical strategy to improve adherence in people at risk of CVD. Although there is a demonstrated benefit in reducing MACE, predominantly in secondary prevention, there are still gaps in its efficacy in primary prevention and reducing total mortality. Therefore, the importance of obtaining long-term results of the polypill effect and how this strategy can be implemented in real practice.
引用
收藏
页码:605 / 615
页数:11
相关论文
共 50 条
  • [21] Polypill Brings Benefits to Patients with Cardiovascular Disease, Both Improving Medication Adherence and Demonstrating the Concept of Chronotherapy [Letter]
    Zhu, Ling -Ling
    Zhou, Quan
    VASCULAR HEALTH AND RISK MANAGEMENT, 2023, 19 : 659 - 660
  • [22] POLYPILL STRATEGY FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISORDERS
    Dabhadkar, K. C.
    Bellam, N.
    DRUGS OF TODAY, 2013, 49 (05) : 317 - 324
  • [23] Polypill Strategy in Secondary Cardiovascular Prevention
    De la Rosa, Alan
    Arrington, Kedzie
    Desai, Rohan
    Acharya, Prakrati C.
    CURRENT CARDIOLOGY REPORTS, 2024, 26 (05) : 443 - 450
  • [24] The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease
    Hedner, Thomas
    Kjeldsen, Sverre E.
    Narkiewicz, Krzysztof
    Oparil, Suzanne
    BLOOD PRESSURE, 2016, 25 (05) : 276 - 279
  • [25] Use of the cardiovascular polypill 40 mg in secondary cardiovascular prevention
    Marzal, Domingo
    Rodriguez Padial, Luis
    Arnaiz, Joan-Albert
    Castro, Almudena
    Cosin, Juan
    Lekuona, Inaki
    Guijarro, Carlos
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2018, 30 (05): : 240 - 247
  • [26] Mediterranean Diet for Primary and Secondary Prevention of Cardiovascular Disease and Mortality: An Updated Systematic Review
    Laffond, Ana
    Rivera-Picon, Cristina
    Rodriguez-Munoz, Pedro Manuel
    Juarez-Vela, Raul
    de Vinaspre-Hernandez, Regina Ruiz
    Navas-Echazarreta, Noelia
    Sanchez-Gonzalez, Juan Luis
    NUTRIENTS, 2023, 15 (15)
  • [27] Polypills for the secondary prevention of cardiovascular disease: effective in improving adherence but are they safe?
    Selak, Vanessa
    Webster, Ruth
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2018, 9 (02) : 157 - 162
  • [28] Polypill in cardiovascular disease prevention: recent advances
    Coca, Antonio
    Castellano, Jose Maria
    Camafort, Miguel
    Fuster, Valentin
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2023, 133 (03):
  • [29] Beyond Cholesterol in the Primary Prevention of Cardiovascular Disease: Is The Polypill the Answer?
    Sanz G.
    Current Cardiovascular Risk Reports, 2011, 5 (1) : 38 - 44
  • [30] Adherence to cardiovascular medication: a review of systematic reviews
    Leslie, K. H.
    McCowan, C.
    Pell, J. P.
    JOURNAL OF PUBLIC HEALTH, 2019, 41 (01) : E84 - E94